STAFF BOARD
Article
CHAIRMAN
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
MARKETING MANAGER
EDITORIAL BOARD
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 20 - Issue 2, March-April 2018
REVIEWS
DIRECT ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION
GÓMEZ HERRERO DIEGO, CARRERA HUESO FRANCISCO JAVIER, POQUET JORNET JAIME EDUARDO, VILA MIRALLES ROCÍO, RAMON BARRIOS MARÍA AUXILIADORA, SANJUAN CERVERO RAFAEL


Oral anticoagulants are recommended for the prevention of stroke in patients with non-valvular atrial fibrillation. Vitamin K antagonists (VKA) have been used for decades for the treatment and prophylaxis of thromboembolic events. However the direct oral anticoagulants (DOAC), the direct thrombin inhibitor dabigatran and the factor Xa activated inhibitor, apixaban, rivaroxaban and edoxaban, have shown superior safety and efficacy in clinical trials, and are presented as a safe, effective and simple alternative to fixed dose administered. Despite the lack of precise laboratory tests, the degree of anticoagulation cannot be quantified, and are influenced by the changes in drug concentrations during the dosing interval, and also the potential drug interactions and lack of antidote, make the selection of appropriate anticoagulant a clinical challenge.

APIXABAN – ATRIAL FIBRILLATION – DABIGATRAN ETEXILATE – EDOXABAN – RIVAROXABAN – STROKE



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25